P. Bunner

Utility of a Prognostic Scoring System for Allogeneic Stem Cell Transplantation in Patients with Chronic Myeloid Leukemia

M. Qazilbash, J. Abraham, J. Lynch, 2003, Acta Haematologica.

Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies.

F. Awan, K. Watkins, M. Hamadani, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation.

P. Hari, M. Pasquini, M. Horowitz, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Sibling donor and recipient immune modulation with atorvastatin for the prophylaxis of acute graft-versus-host disease.

W. Petros, S. Remick, L. Gibson, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Higher infused CD34+ cell dose and overall survival in patients undergoing in vivo T-cell depleted, but not t-cell repleted, allogeneic peripheral blood hematopoietic cell transplantation.

J. Abraham, S. Remick, L. Gibson, 2011, Hematology/oncology and stem cell therapy.

High-Dose Therapy and Autologous Stem Cell Transplantation in Relapsed and Refractory Hodgkin’s Disease: Outcome Based on a Prognostic Model

M. Qazilbash, J. Abraham, J. Lynch, 2003, Acta Haematologica.

A Phase II Study of Midostaurin and 5-Azacitidine for Elderly Patients with Acute Myeloid Leukemia

M. Levis, S. Gerson, H. Lazarus, 2017 .

Thiotepa and fractionated TBI conditioning prior to allogeneic stem cell transplantation for advanced hematologic malignancies: a phase II single institution trial

J. Lynch, S. Ericson, M. Devetten, 2004, Bone Marrow Transplantation.

Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan‐based reduced toxicity conditioning

C. Hofmeister, R. Garzon, G. Phillips, 2011, Hematological oncology.

Prospective, Multicenter Clinical Trial of Atorvastatin-Based Acute Graft-Versus-Host-Disease (aGVHD) Prophylaxis in Recipients of HLA-Matched Related Donor (MRD) and Matched Unrelated Donor (MUD) Allogeneic Hematopoietic Cell Transplantation (alloHCT)

P. Hari, M. Pasquini, M. Horowitz, 2016 .

Complete Response after High‐Dose Chemotherapy and Autologous Hemopoietic Stem Cell Transplatation in Metastatic Breast Cancer Results in Survival Benefit

J. Fay, J. Lynch, G. Hobbs, 2006, The breast journal.

Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan‐based reduced toxicity conditioning

C. Hofmeister, R. Garzon, G. Phillips, 2011, Hematological oncology.